
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
ProstaScint (In-111 capromab pendetide) from Cytogen Corp. is a radiolabeledmonoclonal antibody specific to prostate-specific membrane antigen. Theproduct aids in the staging of prostate cancer, allowing physicians to makecritical distinctions between localized and metastasized disease.





